GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Alkem Laboratories Ltd

Alkem Laboratories: Alkem Medtech Executes Supplementary Agreement for Occlutech Acquisition

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 29 Jun 2026, 09:34 AM IST  ·  BSE ID: 78d14a89-050f-4539-b934-dddec9bec64c
View Original BSE Filing (PDF)
💡
In Simple Terms
Alkem Laboratories' subsidiary signed an additional agreement for its previously announced acquisition of a majority stake in a Swiss company.
🤖 AI Summary
  • Alkem Medtech, a wholly-owned subsidiary, executed a First Supplementary Agreement on June 26, 2026.
  • The agreement pertains to the acquisition of 51% to 55% of Occlutech Holding AG, Switzerland.
  • This follows previous intimations dated February 13, 2026, and March 6, 2026, regarding the acquisition.
  • The initial plan involved Alkem Medtech acquiring a majority stake in Occlutech Holding AG.
🏢 How This Affects the Company
📈
Business Impact
The execution of the supplementary agreement advances the process for Alkem Laboratories' subsidiary to acquire a significant stake in Occlutech Holding AG, a Swiss company.
⚠️
Risk Impact
This event provides an update on the progression of the acquisition, confirming ongoing steps in the transaction.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this status update filing.
👤
Who Is Affected
Existing shareholders are indirectly affected as this signifies a step in Alkem Laboratories' strategic acquisition, which may impact future business composition.
🔍
Management Signal
The execution of the supplementary agreement signals management's continued commitment to completing the acquisition of Occlutech Holding AG.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Announcement of the final closure date and completion of the Occlutech Holding AG acquisition.
Disclosure of financial details or specific terms related to the completed acquisition.
Future board meeting outcomes discussing the integration of Occlutech Holding AG.
LOW RISK This filing is a procedural update on an ongoing acquisition, not indicating new or elevated risks.
💡 Investor Takeaway
Alkem Laboratories' wholly-owned subsidiary, Alkem Medtech, executed a First Supplementary Agreement on June 26, 2026, for acquiring 51% to 55% of Occlutech Holding AG. This confirms the ongoing progression of the previously announced acquisition process.
⚖️ Strengths & Concerns

✅ Positives

  • Execution of the First Supplementary Agreement indicates continued progress towards completing the planned acquisition of Occlutech Holding AG.
  • The transaction expands Alkem Laboratories' subsidiary, Alkem Medtech's, international reach through a stake in a Switzerland-incorporated entity.
❓ Frequently Asked Questions
What is the update regarding Alkem Laboratories' acquisition plans as of June 2026?
Alkem Medtech Private Limited, a wholly-owned subsidiary of Alkem Laboratories, executed a First Supplementary Agreement to the Share Purchase Agreement on June 26, 2026.
Which entity is Alkem Laboratories' subsidiary intending to acquire?
Alkem Medtech Private Limited intends to acquire at least 51% and up to 55% of the total issued equity share capital of M/s. Occlutech Holding AG.
Where is Occlutech Holding AG incorporated?
Occlutech Holding AG is a company incorporated in Switzerland.
What were the previous intimations related to this acquisition?
This update is in continuation of earlier intimations dated February 13, 2026, and March 6, 2026, informing the Stock Exchanges about the acquisition.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.